英文药名:DEPAKOTE® SPRINKLE(DIVALPROEX SODIUM COATED PARTICLES IN CAPSULES)
中文药名:双丙戊酸钠包衣颗粒胶囊
生产厂家:雅培(ABBOTT) 药品介绍: DEPAKOTE® SPRINKLE CAPSULES DIVALPROEX SODIUM COATED PARTICLES IN CAPSULES Administration Guide DEPAKOTE® Sprinkle Capsules DIVALPROEX SODIUM COATED PARTICLES IN CAPSULES DEPAKOTE® Sprinkle Capsules (divalproex sodium coated particles in capsules) may be swallowed whole or the capsule contents may be sprinkled onto soft food such as applesauce or pudding. Serving Suggestions Depakote ® Sprinkle Capsules (divalproex sodium coated particles in capsules) provide the medicine that your healthcare provider has prescribed. The sprinkles are flavorless. Soft foods such as applesauce or pudding are best to use for mixing and taking Depakote Sprinkles. TO ADMINISTER WITH FOOD:
1 |
|
Hold the capsule so that the end marked "THIS END UP" is straight up and the arrow on the capsule is up. The capsule is extra large to help prevent spilling the DEPAKOTE Sprinkles, but it still must be handled carefully. |
2 |
|
To open the capsule, hold it carefully. As shown in the picture, gently twist the capsule apart to separate the top from the bottom. It may be helpful to hold the capsule over the food to which you will add the sprinkles. If you spill any of the capsule contents, start over with a new capsule and a new portion of food. |
3 |
|
Place all the sprinkles onto a small amount (about a teaspoonful) of soft food such as applesauce or pudding. |
4 |
|
Make sure that all of the sprinkle and food mixture is swallowed right away. Do not chew the sprinkle and food mixture. Drinking water right after taking the sprinkle and food mixture will help make sure all sprinkles are swallowed. Throw away any unused sprinkle and food mixture; do not store any sprinkle and food mixture for future use. Mix it each time, right before it is taken. |
Make sure this medicine is taken exactly as your healthcare provider prescribed it. If you have any questions, please contact your healthcare provider or pharmacist. Keep all of your healthcare provider's appointments as scheduled. Make sure that Depakote Sprinkle Capsules and all other medicines are kept out of the reach of children. Note You may see the specially coated particles in Depakote Sprinkle Capsules in stool. If you do, you should inform your healthcare provider. Ask your healthcare provider or pharmacist about possible side effects with Depakote Sprinkle Capsules. Store Depakote Sprinkle Capsules below 77°F (25°C).
DEPAKOTE SPRINKLE Rx Generic Name and Formulations: Divalproex sodium 125mg; coated particles in caps. Company: AbbVie Indications for DEPAKOTE SPRINKLE: Absence seizures. Complex partial seizures. Adults and Children's Dose: May swallow caps whole or sprinkle contents on soft food. <10yrs: not recommended. ≥10yrs: Absence seizures: initially 15mg/kg per day. Complex partial: initially 10–15mg/kg per day. Both: Give in 2–3 divided doses if total daily dose >250mg. Increase weekly if needed by 5–10mg/kg per day; max 60mg/kg per day. See Also: DEPAKOTE DEPAKOTE ER Contraindications: Hepatic disease or significant hepatic dysfunction. Known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG). Suspected POLG-related disorder in children <2years of age. Urea cycle disorders. Warnings/Precautions: Increased risk of hepatotoxicity in patients with congenital metabolic disorders, multiple AEDs, severe seizure disorders with mental retardation, organic brain disorders, esp. in children <2 years of age. Increased risk of major congenital malformations (eg, spina bifida) and decreased IQ scores. Discontinue if hepatic dysfunction, pancreatitis, thrombocytopenia, hyperammonemia, or multi-organ hypersensitivity reactions occur. History of liver disease; monitor liver function and clinical symptoms prior to therapy and at frequent intervals (esp. for 1st 6 months). Follow-up if symptoms of hyperammonemia occur. Suicidal tendencies (monitor). Depakote ER is not bioequivalent to delayed-release tabs on mg/mg basis. Avoid abrupt cessation. Monitor platelets, bleeding time (at baseline, before surgery, and in pregnancy); reevaluate periodically. May affect HIV or CMV viral load (in vitro). Monitor motor and cognitive functions routinely. Elderly (monitor fluid and nutritional intake, and for somnolence). Pregnancy (Cat.D): apprise females of childbearing potential of risks to fetus; avoid, if treatment necessary, use effective contraception. Nursing mothers: not recommended. Interactions: Monitor levels of valproate, ethosuximide, other anticonvulsants, and whenever an enzyme inducer is added or withdrawn. Potentiates carbamazepine, diazepam, ethosuximide, lamotrigine, phenobarbital, phenytoin, tolbutamide, warfarin, zidovudine, amitriptyline, nortriptyline. Potentiated by aspirin, felbamate. Levels reduced by rifampin, phenytoin, carbamazepine, phenobarbital, carbapenem antibiotics. CNS depression with alcohol, other CNS depressants. Clonazepam may induce absence status in patients with history of absence seizures. May interfere with urine ketone and thyroid tests. Others: see full labeling. Adverse Reactions: Abdominal pain, accidental injury, alopecia, ambylopia/blurred vision, amnesia, anorexia, asthenia, ataxia, back pain, bronchitis, constipation, depression, diarrhea, diplopia, dizziness, dyspepsia, dyspnea, ecchymosis, emotional lability, fever, flu syndrome, headache, increased appetite, infection, insomnia, nausea, nervousness, nystagmus, peripheral edema, pharyngitis, rash, rhinitis, somnolence, abnormal thinking, thrombocytopenia, tinnitus, tremor, vomiting, weight gain, weight loss; hepatotoxicity, acute pancreatitis, hyperammonemia. How Supplied: Tabs 125mg—100; Tabs 250mg, 500mg—100, 500; Sprinkle caps—100; ER 250mg—60; ER 250mg, 500mg—100, 500
|